Rituximab, a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, may offer therapeutic value in lupus nephritis unresponsive to standard regimens. In patients with relapsed or ...

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent ...

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and individuals with ARDs not exposed to RTX.

The Attorney General’s Department has filed indictments, before a three-judge bench of the Colombo High Court, against former ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A new clinical test may be able to predict which biologic may be the most effective for each individual with rheumatoid ...

Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without ...

This trial compared ofatumumab with rituximab for people with diffuse large B cell or follicular lymphoma.